Conatus Pharma Breaks From Intercept's Shadow?

Bloggers and traders alike are scratching their heads, looking for answers as to why Conatus Pharmaceuticals (CNAT) is up more than 48% intraday today.

Short of any company comments and my own hubris, Premium subscribers over at PropThink.com profitably know why: "Intercept  Isn't the Only Way to Play Liver Disease."

To wit: [excerpt] "Similarly focused on liver disease treatments, Conatus Pharmaceuticals (CNAT) has risen and fallen on parallel developments for Intercept Pharmaceuticals’ (ICPT) obeticholic acid (OCA). A series of favorable emricasan updates in the next 12 months, including Phase 2 updates in patients with nonalcoholic fatty liver disease (NAFLD) or fibrotic nonalcoholic steatohepatitis (NASH), could allow investors to better assess the commercial opportunities of CNAT’s lead compound – and finally free the stock price from Intercept’s shadow."

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.